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Treatment of diabetic neuropathy is still carried out by providing symptomatic therapy, which
only improves ± 50% of the total symptoms felt by patients, but does not tackle the underlying
causes of the disease. Astaxanthin is a potent antioxidant, anti-inflammatory, and anti-diabetic
carotenoid that could be an additional treatment option. We aimed to measure the effectiveness of
administering astaxanthin as an additional therapy to improve the impact of pain and discomfort
experienced daily by diabetes mellitus patients with painful diabetic neuropathy. We conducted a
randomized experimental study with an open label design of 36 patients who had been diagnosed
with painful diabetic neuropathy. The control group was treated with standard treatment for painful
diabetic neuropathy, and the experimental group was given both standard and additional therapy
of astaxanthin at a dose of 6 mg once per day. The impact of pain was assessed using the Brief Pain
Inventory (BPI) before administering astaxanthin and on the 4th and 8th weeks after administering
astaxanthin. The administration of therapy showed a significant improvement in the impact of pain
experienced daily by patients on both treatment groups (p<0.05). However, the mean BPI score of
the control and the experimental groups did not differ significantly each week (p>0.05). There is a
significant improvement in the BPI of patients with painful diabetic neuropathy who were given
additional treatment (add on) of astaxanthin compared to patients who were only given standard
treatment for painful diabetic neuropathy.
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INTRODUCTION
Diabetes mellitus is one of the non-communicable
diseases with the highest causes of death of about 1.6
million people per year. According to the data stated by
Indonesia’s Basic Health Research in 2018, there were
approximately 16 million of Indonesians who suffered
from diabetes, and it is estimated to increase up to
about 21.3 million people by the year 2030 (Ministry
of Health of the Republic of Indonesia, 2018). Diabetes
is a group of chronic metabolic disorders characterized
by high blood sugar levels (hyperglycemia) caused
by defects in insulin secretion, insulin action, or both
due to the damage of pancreatic β-cells. Mistreatment
or late treatment of diabetes may lead to further
complications. Microvascular complications such
as neuropathy, nephropathy, and retinopathy are the
complications that often occur in diabetic patients
(Wisse, 2018). Unfortunately, about 75% of patients
may be asymptomatic and therefore fail to recognize
the early symptoms of this disease, resulting in further
serious complications or even death (American Diabetes
Association, 2014).

Painful diabetic neuropathy is one of the complications
that often occur in patients with diabetes mellitus (>50%)
and is caused by disruptions in the metabolic and vascular
systems. Symptoms of diabetic neuropathy are prickling
and tingling sensation, numbness, pain with burning
sensation, and stabbing pain in certain body parts (Javed,
Petropoulos, Alam, & Malik, 2015). It is necessary to
provide the appropriate treatment for patients who suffer
from painful diabetic neuropathy as it limits their daily
activities. The treatment available for these patients
is still in the form of symptomatic treatment such as
pregabalin, gabapentin, and amitriptyline, thus requiring
additional treatment (Kaur & Pandhi, 2011). Therefore,
healthcare professional, specifically neurologists and
other general practitioners that often handle neuropathy
patients with the history of diabetes need to provide the
proper treatments and strict glycemic control for diabetic
patients with painful diabetic neuropathy to alleviate the
pain and prevent further progression of painful diabetic
neuropathy to help patients enhance their quality of life
and well-being.
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Astaxanthin, a natural carotenoid that acts as a potent
antioxidant with its anti-diabetic and anti-inflammatory
properties, can can protect nerve damage and reduce
neuroinflammation caused by diabetes. Hence, it can
relieve the pain and other neuropathy symptoms felt
by patients (Davinelli, Scapagnini, & Nielsen, 2018).
Due to this, additional astaxanthin treatment towards
the standard treatment of painful diabetic neuropathy
is required. Previous studies rarely discuss the use of
astaxanthin in symptom improvement, especially in
cases concerning painful diabetic neuropathy (Lin, Wen,
& Tsai, 2018). Previous studies focused more on the use
of astaxanthin in treating retinopathy and nephropathy
that caused by various diseases. One study by Yeh, et
al., (2016) focused more on the use of astaxanthin on
treating retinopathy, while another study by Chen, et
al., (2020) focused more on the use of astaxanthin in
treating retinopathy. Therefore, this study was conducted
to examine the benefits of astaxanthin on improving
the impact of pain relief patients with painful diabetic
neuropathy.
METHODS
Design
This study was conducted with an experimental
randomized controlled trial, active comparator, and an
open-label design.
Subject
This study was conducted on 36 diabetic patients at
Bethesda Hospital Yogyakarta diagnosed with painful
diabetic neuropathy based on Diabetic Neuropathy
Examination (DNE) and Diabetic Neuropathy Symptom
(DNS) who have agreed and signed the given informed
consent.
Assessment
Data retrieval was conducted using secondary
data obtained from the Brief Pain Inventory (BPI)
questionnaire that patients filled out on their selfassessment sheets, by choosing the level of intensity of
the symptoms experienced by the patients on a scale of
0 to 100. Subjects were divided into two groups. The
control group received standard treatment for painful
diabetic neuropathy only (gabapentin, pregabalin, or
a combination with amitriptyline). The experimental
group received both standard and additional astaxanthin
treatment at a dose of 6 mg once per day for eight weeks.
The effect of both treatment groups on the impact of
pain on patient’s daily activities was assessed using
the BPI by questioning 8 items of questions regarding
the symptoms experienced by patients before the
administration of treatment, and on the 4th and 8th weeks
after the administration of the additional treatment. The
assessment aimed to carefully analyze the improvement
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process of painful diabetic neuropathy symptoms in both
groups, which is done by analyzing the mean difference
of BPI scores from week 0 until week 8. Data retrieval
was collected by an enumerator to avoid biases and
obtain valid and reliable data.
Statistical Analysis
The data analysis was performed using the Mann
Whitney test to compare dependent variables or
outcomes between two independent treatment groups.
Ethical Approval
This study has complied with all regulations based on
The Council for International Organizations of Medical
Sciences (CIOMS) 2016 and has received ethical
approval from Bethesda Hospital Yogyakarta’s Health
Research Ethics Commission with ethical approval
number of No. 16/KEPK-RSB/II/21.
RESULTS
Basic Characteristics of Research Subjects
Thirty-six research subjects with confirmed painful
diabetic neuropathy were divided into two groups.
The control and experimental groups. One subject in
the control group was dropped out from the study due
to death by COVID-19 during the study. The research
subjects in both groups consisted of 16 men and 20
women, with an average age of 63.89±8.013 years old, as
shown in Table 1. The comorbid conditions that existed
in most subjects were hypertension, by a record of 23
subjects (63.8%) followed by cardiovascular disease
in 22 subjects (61.1%), and gastrointestinal disease in
4 subjects (0,11%). The most widely used medication
among the subject research is an antihypertensive agent
used by 23 subjects (63.8%), followed by antiplatelet
agents, vitamin B, and statin drugs by 19 (52.7%), 14
(38,8%), and 8 subjects (22,2%) respectively. The mean
score of DNE in the control group was 4.00±0.907,
while in the experimental group was 3.83±0.857 with
a p-value of 0.735. On the other hand, the mean score
of DNS of the control group was 2.39±0.916, while
the experimental group was 2.50±1.04 with a p-value
of 0.736. DNE and DNS scores in both groups did not
differ significantly (p>0.05), as illustrated in Table 2.
All subjects were given standard treatment of 6 mg
astaxanthin that was proven to have the most effective
dose for patients, including study by Tominaga (2009).
Therapy was given with either a single treatment of
gabapentin or pregabalin or combined treatment with
amitriptyline, as shown in Table 3. 100 mg gabapentin
was administered to 15 subjects (83.3%) in the control
group and 17 subjects (94.4%) in the experimental group,
while the prescription of 75 mg pregabalin was given
to 2 subjects (11.1%) in the control group. Combined
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Table 1. Basic characteristics of research subjects

Age (Mean±SD)
Sex
Male
Female
Comorbid Conditions
Hypertension
Yes
No
Cardiovascular Disease
Yes
No
Gastrointestinal Disease
Yes
No
Comedication
Antihypertensive
Yes
No
Antiplatelet
Yes
No
Statin
Yes
No
Vitamin B
Yes
No

Experimental Group

Control Group

n(%)
65.28±7.41

n(%)
62.50±8.549

7(38.9)
11(61.1)

9(50)
9(50)

0.502

11(61.1)
7(38.9)

12(66.7)
6(33.3)

0.729

11(61.1)
7(38.9)

11(61.1)
7(38.9)

1.000

3(16.7)
15(83.3)

1(5.6)
17(94.4)

0.289

11(61.1)
7(38.9)

12(66.7)
6(33.3)

0.729

10(55.6)
8(44.4)

9(50)
9(50)

0.738

4(22.2)
14(77.8)

4(22.2)
14(77.8)

1.000

8(44.4)
10(55.6)

6(33.3)
12(66.7)

0.494

p
0.294

Data presented as n (%) or mean±SD; p, significance between experimental and control group; Independent T-test for normally
distributed data, Mann–Whitney test for abnormally distributed data, Wilcoxon test for comparing the significance between a
pair of data. The statistically significant difference is shown as *(p<0.05).

Table 2. Mean score of DNE and DNS in both research groups

DNE
DNS

Experimental Group
(n=18)
3.83±0.857
2.50±1.04

Control Group
(n=18)
4.00±0.907
2.39±0.916

p
0.735
0.736

Data presented as n; p, significance between experimental and control group; Independent T-test for normally distributed data,
Mann–Whitney test for abnormally distributed data. The statistically significant difference is shown as *(p<0.05).
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Table 3. Standard treatment of both treatment groups
Standard Treatment
Gabapentin 100 mg
Pregabalin 75 mg
Gabapentin 100 mg
+ Amitriptyline 25 mg
Gabapentin 300 mg
+ Amitriptyline 25 mg

Experimental Group
n(%)
17(94.4)
0(0)

Control Group
n(%)
15(83.3)
2(11.1)

p

0(0)

1(5.6)

0.248

1(5.6)

0(0)

Data presented as n; p, significance between experimental and control group; Independent T-test for normally distributed data,
Mann–Whitney test for abnormally distributed data. The statistically significant difference is shown as *(p<0.05).

Table 4. Mean BPI score of experimental group and control group
BPI Score
Pain with burning sensation
Baseline (Week 0)
Week 4
Week 8
Electric shock-like pain
Baseline (Week 0)
Week 4
Week 8
Tingling sensation
Baseline (Week 0)
Week 4
Week 8
Numbness
Baseline (Week 0)
Week 4
Week 8

Experimental Group
(n=18)

Control Group (n=17)

p

17.22±28.657
10±19.704
2.78±7.519

13.33±20.864
8.24±14.246
9.41 ±17.843

0.821
1.000
0.291

22.22±30.785
13.89±23.044
5.56±11.490

21.11±23.736
9.41±17.489
6.47±14.552

0.973
0.545
0.637

43.89±30.705
31.67±31.296
27.22±29.666

25.56±28.537
17.65±20.775
12.35±21.074

0.055
0.217
0.105

41.67±25.952
32.22±27.559
27.78±28.192

43.89±25.699
30.59±26.568
24.71±25.524

0.737
0.776
0.867

Data presented as n; p, significance between experimental and control group; Independent T-test for normally distributed data,
Mann–Whitney test for abnormally distributed data. The statistically significant difference is shown as *(p<0.05).

treatment of 100 mg gabapentin and 25 mg amitriptyline
were prescribed to 1 subject (5.6%) in the control group,
and a combined treatment of 300 mg gabapentin and 25
mg amitriptyline was given to 1 subject (5.6%) in the
experimental group. However, we found out that there
is no difference in standard treatment between both
treatment groups (p>0.05).
Data Analysis
The effectiveness of treatment can be analyzed through
the mean score of the BPI, as displayed in Table 4. First,
the BPI score regarding pain with burning sensation
recorded the highest mean of 17.22 in the experimental
group at week 0. Meanwhile, the lowest mean BPI score
was 2.78, which was found in the experimental group

on the 8th week, as seen in Figure 1. Secondly, the highest
and lowest mean BPI scores of electric shock-like pain
were found in the experimental group, with a score of
22.22 at week 0 and 5.56 at week 8, respectively, and
can be found in Figure 2. Next, the highest mean BPI
score of a tingling sensation was 43.89, found in the
experimental group at week 0, while the lowest mean
BPI score was 12.35, found in the control group on the
8th week that can be seen in Figure 3. Lastly, the highest
and lowest mean BPI score of numbness was found in
the control group at week 0 and week 8, with a score of
43.89 and 24.71, respectively, as seen in Figure 4. The
data analysis concluded that the BPI scores of the two
treatment groups did not differ significantly each week
(p>0.05.)
E-ISSN 2477-0612
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Figure 1. Mean BPI score of pain with burning sensation of experimental
group and control group

Figure 2. Mean BPI Score of electric shock-like pain of experimental
group and control group

Figure 3. Mean BPI score of pain with tingling sensation of experimental
group and control group
E-ISSN 2477-0612
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Figure 4. Mean BPI score of numbness of experimental group and control group
Table 5. Mean difference of BPI score between experimental group and control group
BPI Score
Pain with burning sensation
∆ BPI score week 0-4
∆ BPI score week 4-8
∆ BPI score week 0-8
Electric shock-like pain
∆ BPI score week 0-4
∆ BPI score week 4-8
∆ BPI score week 0-8
Tingling sensation
∆ BPI score week 0-4
∆ BPI score week 4-8
∆ BPI score week 0-8
Numbness
∆ BPI score week 0-4
∆ BPI score week 4-8
∆ BPI score week 0-8

Experimental Group
(n=18)

Control Group (n=17)

p

7.222 ±18.408
7.222 ±18.725
14.444 ±27.272

5.882 ±13.256
-1.176±13.173
4.705±21.247

0.021*
0.3040
0.035*

8.333±16.179
8.333±18.230
16.667±26.121

11.176±19.326
2.941±5.878
14.117±20.934

0.002*
0.007*
0.001*

12.222±16.647
4.444±9.217
16.667 ±18.786

9.411±14.348
5.294 ±13.284
14.705 ±24.268

0.000*
0.010*
0.000*

9.444±9.375
4.444±6.156
13.888±11.447

11.764±13.339
5.882±12.776
17.647 ±22.508

0.000*
0.006*
0.000*

Data presented as n; p, significance between experimental and control group; Independent T-test for normally distributed data,
Mann–Whitney test for abnormally distributed data. The statistically significant difference is shown as *(p<0.05).

The results of data analysis using the Wilcoxon test
showed that the most significant mean difference for
each symptom could be seen on the BPI score of week
0 to week 8, as displayed in Table 5. For that particular
period, the BPI score of pain with a burning sensation
in the experimental group showed the most remarkable
mean difference of 14.445, while for the control group,
it was 4.705 with a p-value of 0.035. Meanwhile, the
mean difference of BPI score of electric shock-like pain
was 16.667 in the experimental group and 14.117 in the
control group with a p-value of 0.001. Simultaneously,
for the tingling sensation symptom, the mean difference

of the BPI score was 16.667 in the experimental group
and 14.705 in the control group with a p-value of 0.010.
While for numbness, the mean difference of the BPI
score was 13.888 and 17.647 in the experimental group
and the control groups, respectively (p-value of 0.000).
The improvement of the mean difference of BPI score in
the impact of pain such as pain with burning sensation,
electric shock-like pain, and the tingling sensation
from week 0 to week 8 was found to be greater in the
experimental group compared to the control group.
Meanwhile, the improvement of the mean difference of
E-ISSN 2477-0612
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BPI score of numbness from week 0 to week 8 was higher
in the control group compared to the experimental group.
The results indicated that treatment in patients, for both
symptomatic only and combined treatment of astaxanthin
with symptomatic treatment, can significantly enhance
the pain relief in patients’ daily activities (p<0.05).
Both treatments have been proven to significantly
reduce the severity of pain’s impact on the patients’
daily activities. The impact of pain or symptoms felt by
patients, such as pain with a burning sensation, electric
shock-like pain, numbness, and tingling sensation,
showed different improvements. The differences might
be due to different mechanisms of the pathophysiological
process of neuropathic pain (“individualized neuropathic
pain based on phenotyping”) and genetic factors.
The most significant improvement was observed in the
improvement of numbness symptoms in the control
group from week 0 to week 8, with the value of 17.647
± 22.508. The second greatest improvement was found
in the improvement of electric shock-like pain in the
experimental group from week 0 to week 8, which
accounted for 16.667 ± 26.121, as well as a tingling
sensation in the experimental group from week 0 to week
8, with a range of 16.667 ± 18.786. The data showed
that the addition of astaxanthin adjunctive therapy in the
standard treatment of symptomatic treatment is better
than symptomatic treatment alone in improving pain
relief in patients.
DISCUSSION
The Role of Astaxanthin in improving The Impact of
Pain in Painful Diabetic Neuropathy Patients
Painful diabetic neuropathy in patients with diabetes
mellitus is caused by a disruption in the vascular
and metabolic systems, resulting in hyperglycemia
conditions which eventually lead to the increased
production of the aldose reductase enzyme. The increase
of this enzyme production can further lead to a buildup of sorbitol and polyols, leading to overproduction of
oxidative stress, increases in (advanced glycation end
products (AGEs), and decreases in nerve growth factor
(NGF), consequently causing damage and inflammation
to nerve cells.
Astaxanthin is a fat-soluble xanthophyll carotenoid
that plays an essential role in treating painful diabetic
neuropathy and other diabetes complications. The
antioxidant, anti-inflammatory, and anti-diabetic
properties of astaxanthin can improve pain relief in
patients’ daily activities. Astaxanthin is neuroprotective
(Lin, Wen, & Tsai, 2018), which means that it will
protect the nervous system against further damage due
to diabetes complications through the inhibition of
E-ISSN 2477-0612
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inflammatory response via nuclear factor kappa-lightchain-enhancer of activated B cells (NF- κB) pathway,
the inhibition of microvascular damage by increasing
vascular endothelial growth factor (VEGF) production,
and the inhibition of apoptosis through the regulation
of a mitogen-activated protein kinase (MAPK) and
PI3K/Akt pathways. Research conducted by Lin, et
al., (2018) proved that astaxanthin has neuroprotective
properties with p<0.05. Another study which resulted
in a p-value of ≤0.0001, also successfully proved that
adjunctive therapy of astaxanthin reduces the pain felt
by patients, repairs metabolic processes or blood supply
to the nervous system, and improves other symptoms of
diabetic neuropathy.
Furthermore, astaxanthin adjunctive therapy on standard
treatment can increase endogenous antioxidants,
glutathione, and NGF. It can decrease AGEs and
malondialdehyde levels. These processes will reduce
oxidative stress and inhibit inflammatory biomarkers,
such as interleukin (IL)-1β, IL-6, and tumor necrosis
factor-alpha (TNF-α). Reduced oxidative stress and
inhibited inflammatory biomarkers can give rise
to insulin production, and decrease insulin resistance
and blood sugar levels. In addition, astaxanthin can also
inhibit the production of inflammation mediators by
suppressing the activation of cyclooxygenase-2 (COX2) and inducible nitric oxide synthase (iNOS) biomarker
protein degradation, which also lead to the suppression
of oxidative stress, cell apoptosis, and the suppression
of chronic neuroinflammation caused by diabetes. Thus,
making astaxanthin a multitargeted therapy.
Interestingly, our results found out that the control and
experimental groups significantly reduced the impact of
pain (p<0.05). However, the average weekly BPI score
did not exhibit a significant difference (p>0.05). This
could be explained due to the abnormal distribution of
data, extensive range of data, and the power of the study,
which was 80%. Power of study is the ability of research
to show significant differences so that a difference of less
than 20% will not appear to be significantly different.
Side Effect
Nevertheless, we discovered that a staxanthin adjunctive
therapy in standard treatment causes a side effect in 1
subject from the experimental group in the form of itching
skin, as shown in Table 6. The symptoms experienced by
the patient are slightly mild and did not lead to severe
complications. Hence, the condition did not require
any further treatment. A study conducted by Davinelli,
Scapagnini, & Nielsen (2018), also reported similar
conditions, where the administration of astaxanthin to
research subjects caused side effects such as pruritus.
Therefore, the side effect might be affected by this study’s
limitations, which was the lack of information about the
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Table 6. Side effect of treatment in experimental group and control group

Side Effect of Treatment
Yes
No

Experimental Group Control Group
(n=18)
(n=17)

p

1 (5.6)
17 (94.4)

1.00

0 (0)
17 (100)

Data presented as n; p, significance between experimental and control group; Independent T-test for normally
distributed data, Mann–Whitney test for abnormally distributed data, Wilcoxon test for comparing the
significance between a pair of data. The statistically significant difference is shown as *(p<0.05).

patient’s past medical history, more importantly about
the patient’s diabetes and allergies history.

International Association for the Study of Pain, 159(3),
569-575.

CONCLUSION

Jankovic, M., Novakovic, I., Nikolic, D., Maksic,
J., Petronic, I., & Cirovic, D. (2021). Genetic and
Epigenomic Modifiers of Diabetic Neuropathy.
International Journal of Molecular Sciences.

In comparison to patients who were only given a
standard treatment such as gabapentin, pregabalin, or
amitriptyline for diabetic neuropathic pain, additional
therapy of astaxanthin at a dose of 6 mg once per day
was found to have significantly improved the BPI in
patients that have been diagnosed with painful diabetic
neuropathy, as seen in the experimental group.
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